{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=51&sponsor=Genentech%2C+Inc.", "query": { "sponsor": "Genentech, Inc.", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 1397, "total_pages": 140, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=52&sponsor=Genentech%2C+Inc.&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=50&sponsor=Genentech%2C+Inc.&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T02:48:16.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03737123", "title": "Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nabil Adra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2018-12-19", "completion_date": "2022-05-18", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737123" }, { "nct_id": "NCT00529503", "title": "A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "SGN-40", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 151, "start_date": "2007-09", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529503" }, { "nct_id": "NCT05961696", "title": "A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-07-05", "completion_date": "2023-10-03", "has_results": false, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05961696" }, { "nct_id": "NCT06014762", "title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (tFL)", "Follicular Lymphoma Grade 3B", "DLBCL", "DLBCL - Diffuse Large B Cell Lymphoma", "DLBCL Arising From Follicular Lymphoma", "DLBCL, Diffused Large B Cell Lymphoma", "DLBCL NOS" ], "interventions": [ { "name": "P-CD19CD20-ALLO1", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-04-16", "completion_date": "2041-03", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 16, "location_summary": "Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06014762" }, { "nct_id": "NCT00417976", "title": "Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Infusional 5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tony Bekaii-Saab", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2015-10-01", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Columbus, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00417976" }, { "nct_id": "NCT02392624", "title": "A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Urticaria" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 206, "start_date": "2015-05-18", "completion_date": "2017-03-09", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 40, "location_summary": "Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392624" }, { "nct_id": "NCT00912340", "title": "Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-05", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Madison, Wisconsin", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00912340" }, { "nct_id": "NCT02724878", "title": "Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Clear Cell Kidney Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2016-07-15", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 4, "location_summary": "La Jolla, California • Boston, Massachusetts • Detroit, Michigan", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724878" }, { "nct_id": "NCT05538208", "title": "The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "8 Years to 20 Years" }, "enrollment_count": 105, "start_date": "2024-06-07", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 19, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538208" }, { "nct_id": "NCT02589717", "title": "An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab [TECENTRIQ]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2015-11", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-31T02:48:16.836Z", "location_count": 40, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 35 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589717" } ] }